November 18, 2026
Health news, explained with evidence
LIVE

Combination Therapy Shows Long-Term Promise for Advanced Thymic Tumors

🔬 Research 2 min read 👁 5

Final phase 2 trial results indicate that pairing lenvatinib with pembrolizumab yields encouraging survival outcomes in pretreated advanced thymic tumors.

Combination Therapy Shows Long-Term Promise for Advanced Thymic Tumors🔬Research

Photo: Medical Xpress

Key points

  • Phase 2 PECATI trial evaluated lenvatinib plus pembrolizumab.
  • Median overall survival reached 40.2 months.
  • Grade 3 or higher adverse events occurred in 44.2% of patients.

Final results from the phase 2 PECATI clinical trial, published in the Journal of Thoracic Oncology, indicate that combining the medications lenvatinib and pembrolizumab may offer a meaningful treatment alternative for patients with advanced B3-thymoma and thymic carcinoma whose condition has advanced after platinum-based chemotherapy. Following a median follow-up period of 24.6 months, investigators documented a median progression-free survival of 22.1 months alongside a median overall survival of 40.2 months.

Thymic epithelial tumors are uncommon malignancies originating in the chest behind the breastbone, with B3-thymoma and thymic carcinoma representing particularly aggressive variants. While initial care typically relies on platinum-based chemotherapy, effective subsequent options remain scarce when the disease advances. The single-arm study involved 43 participants who received oral lenvatinib and intravenous pembrolizumab. Dr. Jordi Remon of Gustave Roussy noted that while the activity data is encouraging, the relatively small sample size and open-label design mean the findings cannot prove definitive superiority over other options or isolate the exact contribution of each individual medication.

Researchers also stressed the necessity of vigilance regarding adverse effects. Grade 3 or higher treatment-related side effects affected 44.2% of participants, leading 27.9% to stop at least one component of the therapy. Immune-related events were documented in 39.5% of individuals, encompassing serious manifestations such as pneumonitis, colitis, myocarditis, and liver toxicity.

What to know

  • Treatment combination: The trial tested lenvatinib alongside pembrolizumab in 43 patients with pretreated advanced thymic cancers.
  • Survival metrics: Median progression-free survival reached 22.1 months, while median overall survival was 40.2 months.
  • Toxicity risks: Serious adverse events were common, requiring close clinical oversight and occasional treatment discontinuation.

Readers should always consult a qualified healthcare provider regarding personal medical decisions and specialized cancer therapies.

Source Medical Xpress — medicalxpress.com/news/2026-11-trial-results-term-survival-lenvatinib.h… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.